Affiliation:
1. I.M. Sechenov First Moscow State Medical University (Sechenov University)
Abstract
Aim. To review data on the efficiency and safety of using Ustekinumab in patients with Crohn’s disease.Key findings. Ustekinumab is a fully human monoclonal antibody of the IgG1k class to the p40 subunit of IL-12 and IL-23. The drug interrupts the cascade of humoral and cellular reactions leading to transmural inflammation of the intestinal wall by blocking the interaction of the p40 subunit with the IL-12Rβ1 chain on the surface of T-lymphocytes and NK cells. A number of placebo-controlled studies have demonstrated the effectiveness of Ustekinumab in the induction and the maintenance of remission in those patients with Crohn’s disease who showed no response to conventional therapy (glucocorticosteroids and immunosuppressants) and therapy with TNF-α antagonists. In addition, the efficiency of Ustekinumab in maintaining a clinical response and clinical remission over two years of therapy has been shown. The drug has a favourable safety profile and a low immunogenicity.Conclusion. The reviewed studies show Ustekinumab to be an effective and safe drug for the induction and the maintenance of clinical remission in patients with Crohn’s disease.
Publisher
Russian Gastroenterolgocial Society
Reference23 articles.
1. Ivashkin V.T., Shelygin Yu.A., Khalif I.L. i dr.Klinicheskie rekomendatsii Rossiiskoi gastroenterologicheskoi assotsiatsii i Assotsiatsii koloproktologov Rossii po diagnostike i lecheniyu bolezni Krona. Koloproktologiya 2017;2(60):7–29. [Ivashkin V.T., Shelygin Yu.A., Khalif I.L. et al. Clinical recommendations of the Russian Gastroenterological Association and the Association of Coloproctologists of Russia on the diagnosis and treatment of Crohn’s disease. Coloproctology 2017;2(60): 7–29 (In Rus.)].
2. Faubion W.A., Loftus E.V., Harmsen W.S., Zinsmeister A.R., Sandborn W.J. The natural history of corticosteroid therapy for inflammatory bowel disease: a populationbased study. Gastroenterology. 2001;121:255–60.
3. Peyrin-Biroulet L., Khosrotehrani K., Carrat F. et al. Increased risk for non-melanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology. 2011;141:1621–8.e1.
4. Beaugerie L., Brousse N, Bouvier A.M. et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617–25.
5. Bourrier A., Carrat F., Colombel J.F. et al. Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Aliment. Pharmacol. Ther. 2016;43:252–61.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献